Skip to main
NUVB

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio is expected to see significant revenue growth from its product candidate, taletrectinib, which is a highly effective, orally administered treatment for ROS1+ NSCLC. Additionally, the company's pipeline of other oncology product candidates and out-licensing collaborations provides a diverse range of revenue streams. Potential risks include negative clinical data for pipeline programs and slower-than-anticipated commercial uptake, but the company's strong management team and focus on educating the NSCLC community bode well for future success.

Bears say

Nuvation Bio is facing near-term commercialization risks for Ibtrozi and regulatory risks for Safusidenib, which would impact future product revenue. Although the company has a strong financial position with $533.7MM in cash, the market may be underestimating the differentiated potential of Safusidenib in IDH1-mutant glioma and the potential of its DDC platform. Therefore, the negative outlook is due to the uncertainty and risks associated with the company's current and future product revenue.

Nuvation Bio (NUVB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 8 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.